en
Choosing Wisely

Benzodiazepine Indietro

LINEE GUIDA PER IL PERSONALE CURANTE

Per eventuali domande, rivolgersi al Centro di competenza sul farmaco dell’Istituto di Scienze Farmacologiche della Svizzera Italiana (CentroFarmaco.ISFSI@eoc.ch).

LETTERATURA CONSIGLIATA

 1. Prescribing drugs of dependence in general practice. Part B-Benzodiazepines, Melbourne: The royal Australian college of General Practitioners. 2015

2. M. Lader et al. Benzodiazepine harm: how can it be reduced? Br J Clin pharmacol 2014; Feb 77(2): 295-301

3. Billotti de Gage S et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ 2012:345

4. Yaffe et al. Benzodiazepine use and risk of Alzeihmer’s disease: case-control study. BMJ 2014; 349doi:10.11136bmjj.g5205 (Published 9 September 2014)

5. Gray Sl et al. Benzodiazepines use and risk of incident dementia or cognitive decline: Prospective population based study. BMJ 2016; 352:i90doi:10.1136/bmj.i906

6. MR De Jong et al. Drug-related falls in older patients: implicated drugs, consequences, and possible prevention strategies. Ther Adv Drug Saf (2013); 4(4): 147-154

7. J Class et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ doi:10.1136/bmj.38623.768588.47 (published 11 November 2005)

8. Buscemi N et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Med 2007; 22 (9)):1335-1350

9. NPS News Number 67.2010 Addressing hypnotic medication use in primary care. Disponibile sul sito: www.nps.org.au

10. BM MacDonald et al. Management of insomnia disorder. Comparative effectiveness review No.159 (prepared by the Minnesota Evidence-based practice Center); December 2015, www.effectivehealthcare.ahrq.gov/reports/final.cfm

11. Barker M et al. Cognitive effects of long-term benzodiazepines use: a meta-analysis. CNS drugs 2004; 4(18):37-48

12. Verdaux H et al. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of the epidemiological studies. Psychol Med 2005; 35:307-315

13. A guide to deprescribing Benzodiazepines, An Australian government Initiative

14. Deprescribing.org, Bruyère Research Institute (Ontario), Centre de recherche, Institut Universitaire de Gériatrie de Montréal

15. Farach et al. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety disorders 2012;26(8):833-843

16. Koen N et al. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neuroscience 2011; 13:423-437

17. Reinhold JA et al. Pharmacological treatment for generalised anxiety disorders in adults: an update. Exp Opinion Pharmacoter 2015; 16(11)1669-1681

18. Baldwin et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analyis. BMJ 2011; 342:d1199doi:10.1136/bmj.d1199

19. Pharmacotherapy for generalized anxiety disorder in adults, UpToDate , versione 30 del 25.4.2016

20. Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy, UpToDate versione 17 del 2 agosto 2016

21. D. O’Mahony et al STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and Ageing 2014; 0:1-6

22. Reeve E et al. A systematic review of interventions to deprescribe benzodiazepines and other hypnotis among older people. Eur J Clin Pharmacol 2017; doi: 10.1007/s00228-017-2257-8

23. Tannembaum C et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education. The EMPOWER cluster randomised trial. JAMA Intern Med 2014; 174(6): 890-898

24. Université de Montréal: “Aînés et somnifères: lespatients informés font des choix sensés (15.4.2017),consulté le 21.6.20017. sito www.nouvelles.montreal.ca

25. Vicens C. et al. Comparative efficacy of two interventions to discontinue long-term benzodiazepines use: cluster randomised controlled trial in primary care. Br J Psichiatry 2014; 2014:471-479


26. Iyer S et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs aging 2008; 25: 1021-1031


27. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry 1987; 48(suppl):12-16


28. Dikeos DC et al. The pharmacology of insomnia: efficacy and reboud with hypnotic drugs. Primary Care Companion.Clin Psychiatry 2002; 4 (suppl 1): 27-32

Ultimo aggiornamento: 19 febbraio 2018
Indietro